SOMATULINE AUTOGEL SOLUTION (EXTENDED RELEASE)

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

LANREOTIDE (LANREOTIDE ACETATE)

Pieejams no:

IPSEN BIOPHARMACEUTICALS CANADA INC

ATĶ kods:

H01CB03

SNN (starptautisko nepatentēto nosaukumu):

LANREOTIDE

Deva:

60MG

Zāļu forma:

SOLUTION (EXTENDED RELEASE)

Kompozīcija:

LANREOTIDE (LANREOTIDE ACETATE) 60MG

Ievadīšanas:

SUBCUTANEOUS

Vienības iepakojumā:

60MG/SYRINGE

Receptes veids:

Prescription

Ārstniecības joma:

OTHER MISCELLANEOUS THERAPEUTIC AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0151653006; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2010-09-13

Produkta apraksts

_SOMATULINE_
_®_
_ AUTOGEL_
_®_
_ _(lanreotide injection)_ _
_Page 1 of 57_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SOMATULINE
® AUTOGEL
®
lanreotide injection
Extended release solution
60 mg, 90 mg, 120 mg lanreotide (as lanreotide acetate)/unit
(syringe), subcutaneous
Antigrowth hormone
Ipsen Biopharmaceuticals Canada Inc.
5050 Satellite Drive, Suite 500
Mississauga, Ontario
L4W 0G1
www.ipsen.ca
Date of Initial Authorization:
JUL 17, 2006
Date of Revision:
AUG 08, 2023
Submission Control Number: 268030
_ _
_SOMATULINE_
_®_
_ AUTOGEL_
_®_
_ (lanreotide injection) _
_Page 2 of 57_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential, Fertility
12/2022
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential, Teratogenic Risk
12/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
12/2022
7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic
06/2023
11 STORAGE, STABILITY AND DISPOSAL
08/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED
.
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
.............................................................................................................
4
1.2
Geriatrics
.............................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
...................................................... 5
4
DOSAGE AND ADMINISTRATION
..............................................................................
5
4.1
Dosing Considerations
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
..................................................... 6
4.3
Reconsti